# Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma

> **NCT00338988** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 44 (actual)

## Conditions studied

- Cancer of the Gallbladder
- Cancer of the Biliary Tract

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00338988
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2012-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00338988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00338988, "Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00338988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*